ERAWATCH Country Reports 2009: Romania. Analysis of policy mixes to foster R&D investment and to contribute to the ERA

The main objective of the ERAWATCH Policy Mix Country reports 2009 is to characterise and assess in a structured manner the evolution of the national policy mixes in the perspective of the Lisbon goals, with a particular focus on the national R&D investments targets and on the realisation and better governance of the European Research Area. The reports were produced for all EU Member State and five Associated States to support the mutual learning process and the monitoring of Member and Associated States' efforts by DG-RTD in the context of the Lisbon Strategy and the European Research Area. The country reports 2009 build and extend on the analysis provided by analytical country reports 2008 and on a synthesis of information from the ERAWATCH Research Inventory and other important available information sources.JRC.J.3-Knowledge for Growt

Research and Innovation Challenges and Policy Responses in Member States

The report on research and innovation challenges and policy responses in Member States highlights recent, topical STI policy developments in these countries, mostly stocktaking on ERAWATCH 2010 Country Reports but also taking into account various other sources. Moreover, it synthesises these national policy trends and policy contexts for each country as well as it runs comparative analysis within and across 8 country groups, the latter clustering countries of similar innovation performance. In this way, we are able to deduct policy implications with regard to the Common Strategic Framework and the Innovation Union Flagship Initiative.JRC.J.2-Knowledge for Growt

RIO Country Report 2017: Romania

The R&I Observatory country report 2017 provides a brief analysis of the R&I system covering the economic context, main actors, funding trends & human resources, policies to address R&I challenges, and R&I in national and regional smart specialisation strategies. Data is from Eurostat, unless otherwise referenced and is correct as at January 2018. Data used from other international sources is also correct to that date. The report provides a state-of-play and analysis of the national level R&I system and its challenges, to support the European Semester.JRC.B.7-Knowledge for Finance, Innovation and Growt

ERA Communication Synthesis Report

This report is a synthesis of progress towards achievement of the ERA, based on an analysis of country data on the five ERA priorities (as defined in the 2012 EC Communication) collected with the support of independent country experts in the first semester 2013, complemented by other relevant indicators and study results (taking into account in some cases limitations regarding data availability and quality). It offers a synthetic and cross-country analytical overview by ERA priority of relevant policies and related policy support measures adopted and implemented (including necessary legal changes enacted) in EU Member States. It covers the 28 EU Member States and 13 Associated Countries. This report aims to identify behavioural patterns across countries, take into account progress in relation to the ERA baseline indicators, and contribute to the ERA Monitoring Mechanism.JRC.J.2-Knowledge for Growt

ERA Fabric Map - Second Edition

This ERA fabric map gives a snapshot of the ERA today. It looks at the division of responsibilities between EU and Member States, and at institutions and bodies involved in the European research system. Starting from the six ERA dimensions described in the ERA Green Paper, the report then looks where we are today, and which direction the future is taking, given the policy context of Europe 2020. Involvement of stakeholders in further building the ERA is looked at by analysing their involvement in a number of existing ERA instruments, using a taxonomy of stakeholder roles and functions. The report has been written as part of the FP7 project Forward Visions on the European Research Area (VERA). This first edition will be updated twice as part of the VERA project.JRC.J.2-Knowledge for Growt

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

RIO Country Report 2016: Romania

The 2016 series of the RIO Country Report analyses and assesses the development and performance of the national research and innovation system of the EU-28 Member States and related policies with the aim of monitoring and evaluating the EU policy implementation as well as facilitating policy learning in the Member States.JRC.B.7-Knowledge for Finance, Innovation and Growt

Magnetic transitions in Fe2O3 nanowires

Magnetic transitions in single-crystal Fe2O3 hematite nanowires, grown by thermal oxidation of iron powder, have been studied in the range of 5-1023 K with a superconducting quantum interference device below room temperature and with a vibrating sample magnetometer at higher temperatures. The broad temperature range covered enables us to compare magnetic transitions in the nanowires with the transitions reported for bulk hematite. Morin temperatures TM of the nanowires and of hematite bulk reference powder were found to be 123 and 263 K, respectively. Also the Néel temperature TN of the nanowires, 852 K, was lower than the bulk TN value. Measurements of the magnetization as a function of temperature show an enhanced signal in the nanowires, which suggests a decrease in the antiferromagnetic coupling. A coercive field observed below TM in the hysteresis loops of the nanowires is tentatively explained by the presence of a magnetic phase.JRC.J.3-Knowledge for Growt

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div